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Background: The use of clinical MRI scanners to conduct pre-clinical research facilitates comparisons with clinical studies. Here
the utility and sensitivity of anatomical and functional MRI data/biomarkers acquired from transgenic mouse models of
neuroblastoma using a dedicated radiofrequency (RF) coil on a clinical 3T scanner was evaluated.
Methods: Multiparametric MRI of transgenic mice bearing abdominal neuroblastomas was performed at 3T, and data cross-
referenced to that acquired from the same mice on a pre-clinical 7T MRI system. T2-weighted imaging, quantitation of the native
longitudinal relaxation time (T1) and the transverse relaxation rate (R2*), and dynamic contrast-enhanced (DCE)-MRI, was used to
assess tumour volume, phenotype and response to cyclophosphamide or cabozantinib.
Results: Excellent T2-weighted image contrast enabled clear tumour delineation at 3T. Significant correlations of tumour volume
(R¼ 0.98, Po0.0001) and R2* (R¼ 0.87, Po0.002) measured at 3 and 7T were established. Mice with neuroblastomas harbouring
the anaplastic lymphoma kinase mutation exhibited a significantly slower R2* (Po0.001), consistent with impaired tumour
perfusion. DCE-MRI was performed simultaneously on three transgenic mice, yielding estimates of Ktrans for each tumour (median
Ktrans values of 0.202, 0.168 and 0.114min 1). Cyclophosphamide elicited a significant reduction in both tumour burden (Po0.002)
and native T1 (Po0.01), whereas cabozantinib induced significant (Po0.01) tumour growth delay.
Conclusions: Simultaneous multiparametric MRI of multiple tumour-bearing animals using this coil arrangement at 3T can provide
high efficiency/throughput for both phenotypic characterisation and evaluation of novel therapeutics, and facilitate the
introduction of functional MRI biomarkers into aligned imaging-embedded clinical trials.
High field (44.7T) small animal dedicated MRI systems that
provide high resolution and signal to noise ratios (SNR) have and
continue to be the preferred platform for pre-clinical imaging
investigations. The physical contrast characteristics and imaging
performance of such pre-clinical scanners differs substantially from
clinical MRI systems. The use of clinical scanners to conduct
pre-clinical research is attractive, as it facilitates a more direct
comparison with clinical studies, the application and development
of clinically applicable imaging protocols, matching of field
strength-related mechanisms such as relaxation, and provides
evidence to support the clinical relevance of functional MRI data/
biomarkers (Brockmann et al, 2007; Chen et al, 2007; Inderbitzin
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et al, 2007; Linn et al, 2007; Bilgen, 2013). This approach also
benefits from the hardware and software advances continuously
being made on modern clinical MRI systems, such as parallel
transmit and receive technology, motion and contrast tracking,
k-space under-sampling and view-sharing strategies (Ullman et al,
2004; Wech et al, 2012; Jerome et al, 2016). Additionally, the
generous homogeneous field region of clinical scanners allows for
high quality, whole-body pre-clinical imaging, and the potential for
simultaneous data acquisition from several subjects during the
same scanning session (Dazai et al, 2004; Nieman et al, 2007).
Nuclear relaxation times are also often better differentiated at
relatively lower field strengths (de Graaf et al, 2006), leading to
superior contrast between imaged soft tissues, crucial for reliable
organ and pathology delineation.
Most clinical scanners operate at between 1 and 3T, having
lower SNR levels than pre-clinical high field systems, and hence
reduced image quality if standard clinical imaging coils are used.
This is exacerbated particularly when imaging the small fields-of-
view necessary while using rodents, but with a high enough
resolution to be able to accurately resolve lesions and acquire
meaningful functional data. One approach of increasing SNR is to
use small dedicated radiofrequency (RF) receiver coils. Such coils
can be designed to fit closely to the object of interest, giving a better
coupling between the object and coil (high filling factor), a stronger
signal and thus improved image quality.
In pre-clinical cancer research performed in vivo, transgenic
mouse models, in which tumours are driven by expression of the
target gene of interest and arise spontaneously within the native
tissue of origin, are being increasingly exploited (de Jong et al,
2014). These models more faithfully emulate human tumour
growth, tumour-host stromal interactions and vasculature, meta-
static potential and therapeutic response in vivo. Such models
demand non-invasive methods to longitudinally and accurately
assess the progression and treatment response of tumours that
typically arise within deep-seated anatomical locations.
The purpose of this study was to evaluate the utility and
sensitivity of a non-bespoke high resolution RF coil for use on a
clinical 3T scanner for the acquisition of anatomical and functional
MRI data/biomarkers from transgenic mouse models of neuro-
blastoma in vivo.
MATERIALS AND METHODS
All procedures involving animals were performed in accordance
with the local ethical review panel, the UK Home Office Animals
(Scientific Procedures) Act 1986, the United Kingdom National
Cancer Research Institute guidelines for the welfare of animals in
cancer research and the ARRIVE guidelines (Workman et al, 2010;
Kilkenny et al, 2010).
T1 phantom. To assess the linearity of T1 measurements on both
the 3 and 7T platforms, phantoms with increasing concentrations
of gadolinium (from 30 to 500 nM) were imaged in both scanners at
ambient temperature. These solutions were transferred into 5mm
NMR tubes, which in turn were placed in 50ml falcon tubes and
restrained using dental paste to limit motion artefacts. The
phantoms were scanned four times on each scanner, and the
average value used to assess the T1 field dependence.
Transgenic mouse models and drug treatment. The aberrant
expression of the transcription factor MYCN is a potent oncogenic
stimulus in cancer. MYCN expression correlates with an aggressive
tumour phenotype, enhanced tumour angiogenesis and poor
clinical prognosis in neuroblastoma (Maris, 2010). Many paediatric
cancers arise through the aberrant expression of just a few driver
genes, and are thus amenable to transgenic mouse modelling
approaches (Chesler and Weiss, 2011). For example, targeted
overexpression of MYCN to the neural crest under the control of
the tyrosine hydroxylase promoter resulted in the Th-MYCN
transgenic mouse model in which abdominal tumours sponta-
neously develop that faithfully replicate the disease biology of high-
risk neuroblastoma (Weiss et al, 1997). More recently, the
identification of mutations in the anaplastic lymphoma kinase
(ALK) gene in neuroblastoma, and its close association withMYCN
amplification, stimulated the development of a novel double
transgenic mouse model for ALK andMYCN (Berry et al, 2012). In
both the Th-MYCN and Th-ALKF1174L/Th-MYCN transgenic mice,
solid tumours spontaneously arise within the retroperitoneum in
peri-renal and para-spinal abdominal regions, consistent with the
typical clinical distribution and radiological presentation of human
neuroblastoma.
In this study, male and female tumour-bearing Th-MYCN and
Th-ALKF1174L/Th-MYCN mice, initially identified by palpation,
underwent MRI at around 50 and 30 days old, respectively (Berry
et al, 2012; Rasmuson et al, 2012). Their genotype was confirmed
by analysing DNA from the tail using real-time quantitative reverse
transcription polymerase chain reaction.
MRI data acquisition
Study protocol. Twenty-three transgenic mice (Th-MYCN n¼ 14,
Th-ALKF1174L/Th-MYCN n¼ 9) underwent imaging on the 3T
platform. Of these, 10 mice (Th-MYCN n¼ 7, Th-ALKF1174L/Th-
MYCN n¼ 3) were scanned at both 3 and 7T within 24 h of each
other in order to compare tumour volume determination and
quantification of tumour R2* at 3 and 7T. Dynamic contrast-
enhanced (DCE)-MRI was performed simultaneously on three Th-
MYCN mice at 3T. To evaluate the 3T platform for imaging-
embedded intervention trials, anatomical and functional (native T1
and R2*) MRI measurements were acquired from Th-MYCN
tumours prior to and 24 h post-treatment with either saline
(control, n¼ 4) or a single 25mg kg 1 i.p. dose of the DNA
alkylating agent cyclophosphamide (CPM, n¼ 5), or prior to and
48 h post treatment with a daily oral dose of either water (control,
n¼ 4) or 30mg kg 1 of the multi-kinase inhibitor cabozantinib
(CBZ, n¼ 5) (Yakes et al, 2011).
3T data acquisition and analysis. MRI data was acquired on a
clinical scanner (Philips Achieva, Best, Netherlands) using a
dedicated high-resolution RF coil (‘Mouse Hotel’, Philips, Best,
Netherlands) (Figure 1). The coil consists of three 40mm inner
diameter solenoids, with the long axis oriented perpendicular to
the magnet B0 field. This coil arrangement enables the simulta-
neous acquisition of MRI data from up to three animals using
independent receiver channels. The 3T imaging protocol, which
included T2-weighted, T1 and R2* measurements, was tested and
optimised using phantoms prior to the in vivo study. A
compromise between SNR, spatial and temporal resolution was
prioritised over a direct parameter match to pre-clinical 7T
protocols.
Anaesthesia was induced by intraperitoneal injection of
midazolam (5mg kg 1), fentanyl (0.05mg kg 1), and medetomi-
dine (0.5mg kg 1) in sterile water. For 3T data acquisition, up to
three anaesthetised mice were positioned supine with their
abdomens in the centre of each individual element of the coil.
Mouse core body temperature was maintained by a built-in heating
system controlled within the ‘Mouse Hotel’ coil.
Initially, whole body anatomical T2-weighted images were
acquired at 3T using a coronal orientation with full anatomical
coverage of all three animals (TSE, 20 slices, slice thickness: 1mm,
FOV¼ 250 200mm, resolution¼ 0.2 0.2mm, ETL¼ 14, TE/
TR¼ 80/3000ms, NSA¼ 1, TA¼ 3min 48 s). T2-weighted images
were used to assess the extent of the disease and aid axial sequence
planning, which was performed across the central part of the
tumour. Proton density and T1-weighted images were then
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acquired using a 3D spoiled gradient echo sequence with variable
flip angle (axial orientation, 7 slices, slice thickness: 1.5mm,
resolution¼ 0.25 0.25mm, FOV¼ 200 85mm, FA¼ 3 and
161, 10 dummy scans, TE/TR¼ 2.3/7ms, NSA¼ 1, TA¼ 27 s).
Multigradient echo (MGE) images were acquired using a 2D
gradient echo sequence with multiple echo times (axial orientation,
3 slices, slice thickness: 1.5mm, resolution¼ 0.3 0.3mm,
FOV¼ 200 50mm, FA¼ 241, TE¼ 4.6, 11.5, 18.4, 25.3, 32.2
and 39.1ms, TR¼ 500ms, NSA¼ 1, TA¼ 30 s). No fat suppres-
sion was employed.
For the acquisition of DCE-MRI data, a lateral tail vein of each
mouse was cannulated with a 27G butterfly catheter connected to
a 10m long line of polyethylene tubing (BPTE-T10, 0.2300 i.d.,
0.38 00 o.d.), and attached through the available wave-guides to
syringe pumps located in the scanner control room, thereby
enabling the simultaneous remote intravenous administration of
contrast agent to each mouse. DCE-MRI data were acquired
using the 3D spoiled gradient echo sequence with 200 time
points, a temporal resolution of 2.5 s and a total acquisition time
of 8mins 33 s. A bolus injection of 0.1mmol kg 1 gadopentate
dimeglumine (Gd-DTPA) was simultaneously administered to all
three mice at a rate of 2mlmin 1, 30 s after the start of the
dynamic acquisition. The total 3T protocol scanning time was less
than 15min.
Tumour volumes were extrapolated from manually drawn
regions of interest (ROIs) on T2-weighted images for each
tumour-containing slice, where clear delineation of tumour could
be determined, using OsiriX Lite (Pixmeo). The T1-weighted
images were analysed using dedicated software (MRIW, working
under IDL, (d’Arcy et al, 2006)), and the ratio between the proton
density (FA¼ 31) and T1-weighted (FA¼ 161) 3D spoiled
gradient echo used to provide estimates of the native tumour
spin-lattice relaxation time T1 (ms) (Fram et al, 1987). The MGE
data were analysed using another dedicated software (ADEPT,
working under IDL (Doran et al, 2012)), with tumour R2* (s
 1)
maps calculated by fitting a single exponential to the signal
intensity echo time curve on a voxel-by-voxel basis using a
Bayesian maximum a posteriori approach (Walker-Samuel et al,
2010). MRIW was used to fit the DCE-MRI data incorporating
the Kety model (Tofts et al, 1999) and a literature-derived murine
arterial input function (Benjaminsen et al, 2004), providing
estimates of Ktrans (min 1), the volume transfer constant between
blood plasma and extracellular extravascular space, Ve (dimen-
sionless volume fraction, and IAUGC60 (mM.s), the initial area
under the gadolinium concentration curve from 0 to 60 s after
injection of Gd-DTPA.
7T data acquisition and analysis. Volumetric analysis and
quantification of T1 and R2* of tumours arising within Th-MYCN
and Th-ALKF1174L/Th-MYCN transgenic mice was performed on a
7T horizontal bore microimaging system (Bruker Instruments,
Ettlingen, Germany) using a 3-cm birdcage volume coil, as
previously described (Jamin et al, 2013, 2014).
Statistical analysis. Statistical analysis was performed using
GraphPad Prism 6. The absolute values for tumour volume,
and median values for T1 and R2* were used. Any significant
difference within the same group was identified using Student’s
two-tailed paired t-test, with a 5% level of significance. Any
significant difference between groups after treatment was tested
using an unpaired t-test. The linear correlation coefficient R was
used to test correlation strength, direction and linear association
between volumes and relaxation times measured at both field
strengths.
RESULTS
Measurements from the T1 phantom for all Gd-DTPA concentra-
tions at both field strengths are shown in Table 1. A highly
significant correlation (R¼ 0.99, Po0.0001) was found
between the T1 values obtained from the 3T clinical scanner and
the 7T pre-clinical scanner, with the median T1 values being higher
at 7T.
Representative anatomical T2-weighted MR images of tumour-
bearing mice acquired at 3 and 7T are displayed in Figure 2A and
B, revealing large peri-renal masses within each mouse abdomen,
and occasionally an additional thoracic tumour, consistent with the
radiological presentation of neuroblastoma. The excellent image
Figure 1. ‘Mouse hotel’ coil and the 3T clinical scanner. Photographs of the coil arrangement on the 3T scanner, and the high resolution 3-
channel/3-animal MR RF coil. The yellow arrows indicate the three individual mouse beds and the red circles the centre of each element of the coil.
Positioning of the coil in the scanner as shown means the mice are perpendicular to the B0 field.
Table 1. Longitudinal relaxation times quantified from the
gadolinium phantoms at 3 and 7T
[Gd] 7T 3T
Saline 2358±21 1608±223
30 nM 1811±34 1238±84
40 nM 1605±14 1002±83
50 nM 1499±15 950±132
100 nM 1227±178 704±7
500 nM 400±4 241±3
T1 values (ms) were determined from solutions of increasing concentration of gadopentate
measured four times on the clinical 3T and pre-clinical 7T MRI scanners. Data are mean of
the medians±1 s.e.m.
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contrast yielded clear tumour delineation across contiguous slices
that could be used for accurate volumetric analysis in vivo. No
significant difference was found between volumetric measurements
acquired at the different field strengths (mean tumour volume
819±153mm3 at 3T vs 889±191mm3 at 7T, n¼ 10, P40.05),
and which were significantly correlated (R¼ 0.98, Po0.0001,
Figure 2C).
Parametric R2* maps from a tumour arising in a Th-MYCN
mouse acquired at both 3 and 7T are shown in Figure 3A. While
anatomical T2-weighted images revealed some anticipated differ-
ences in animal positioning, it was possible to identify similar
tumour positions at both field strengths. A heterogeneous
distribution of R2* values was apparent across all tumours imaged
at both field strengths. A statistically significant positive correlation
of R2* values quantified at 3 and 7T was determined (n¼ 10,
R¼ 0.87, P¼ 0.0012, Figure 3B). Unlike the phantom data, no
significant correlation in tumour T1 relaxation times measured at 3
and 7T in vivo was found. This may be a consequence of different
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Figure 2. Anatomical imaging at 3 and 7T. (A) Anatomical T2-weighted coronal images acquired simultaneously from three Th-MYCN mice with
abdominal neuroblastoma using the high resolution 3-channel/3-animal MR RF coil on the 3T clinical scanner, with a scale bar in blue. Each tumour
is indicated by yellow arrows, with kidney (K) and lungs (L) also annotated. An additional thoracic lesion identified in one of the mice is indicated
with a red arrow. (B) Expanded T2-weighted image of the abdomen of the first mouse in (A) acquired at 3T, and the corresponding T2-weighted
image acquired from the same mouse at 7T, with corresponding scale bars in blue. (C) Linear regression analysis of the volumetric measurements
determined from T2-weighted MRI of tumour-bearing transgenic mice imaged at 3 and 7T revealed a positive and highly significant correlation
(R¼ 0.98, Po0.0001).
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methods of T1 quantification (multiple slice variable flip angle
approach at 3T vs single slice inversion-recovery at 7T),
impossibility of achieving the exact same positioning and acquiring
data from the same central slice on the two imaging platforms, and
the absence of any B1 correction for the data acquired at 3T.
Parametric maps of native T1 and R2* obtained at 3T from
representative Th-MYCN and Th-ALKF1174L/Th-MYCN mice are
shown in Figure 3C and D. A more homogeneous distribution
of both T1 and R2* values was apparent in tumours arising in the
Th-ALKF1174L/Th-MYCN mice. The quantitative data are sum-
marised in Figure 3E and F. While there was no significant
difference in native tumour T1 between the Th-MYCN and the Th-
ALKF1174L/Th-MYCN mice (1098±71ms and 1149±118ms;
P40.1), R2* was significantly faster in tumours in the Th-MYCN
mice when compared to the Th-ALKF1174L/Th-MYCN cohort
(49.7±4 s 1 and 27.7±3 s 1; P¼ 0.0007).
DCE-MRI was successfully performed on three transgenic mice
simultaneously using the 3T platform, yielding data with sufficient
temporal and spatial resolution to evaluate vascular biomarkers of
each imaged tumour in vivo. Pharmacokinetic modelling was
employed to derive and spatially map DCE-MRI parameters.
Parametric Ktrans maps obtained from each tumour-bearing mouse
are shown in Figure 4, along with representative contrast agent
uptake curves obtained from ROIs positioned over the tumour,
kidney and paraspinal muscle. The mean of median and range
values of Ktrans, Ve and IAUGC60 acquired from the three
simultaneously imaged animals were 0.161min 1 (0.124–
0.202min 1), 0.396 (0.374–0.415) and 3.28 (2.38–4.27) mM.s,
respectively.
Anatomical images and parametric maps acquired from
representative Th-MYCN mice prior to and 24 h after treatment
with saline or CPM are shown alongside individual tumour
volume, T1 and R2* values in Figure 5A–C, and summarised in
Figure 5D. Treatment with CPM elicited a significant (P¼ 0.0015)
reduction in tumour burden, and was associated with a significant
decrease in native T1 (P¼ 0.0085). Collectively this translated to a
significant difference in both relative tumour volume (P¼ 0.0004)
and native T1 (P¼ 0.0035) between the control and CPM groups
(Figure 5D). There was no significant treatment-induced change in
any parameter over 24 h in the control cohort. Treatment with
CBZ elicited marked tumour growth delay compared to control,
resulting in a significant difference in the relative tumour volume
(P¼ 0.0076). There was however no associated significant change
in relative native T1 or R2* with CBZ, and no significant treatment-
induced change in any parameter over 48 h in the control group
(summarised in Figure 5E).
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Figure 3. Functional MRI of neuroblastomas at 3 and 7T. (A) Parametric R2* maps acquired at 3 and 7T from the same
Th-MYCN transgenic mouse bearing an abdominal neuroblastoma. Note the difference in dynamic range used to display the R2* maps at the two
field strengths. (B) Linear regression analysis of R2* measurements obtained from tumour-bearing transgenic mice imaged at both 3 and 7T
revealed a significant positive correlation (R¼0.87, P¼0.0012). Parametric (C) T1 and (D) R2* maps acquired at 3T from representative
tumour-bearing Th-MYCN and Th-ALKF1174L/Th-MYCN transgenic mice. Summary plots showing the quantitative data for (E) native T1 and (F) R2*.
Data are individual tumour medians, and the mean±1 s.e.m., ***Po0.001.
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DISCUSSION
Pre-existing and new clinical MRI scanners operating between 1
and 3T, available to clinically orientated research groups, are
being increasingly used for pre-clinical imaging studies in
rodents (Dazai et al, 2004; Brockmann et al, 2007; Chen et al,
2007; Inderbitzin et al, 2007; Linn et al, 2007; Nieman et al, 2007;
Jerome et al, 2016). The potential and advantages of simulta-
neous MRI of multiple tumour-bearing animals has been
highlighted (Dazai et al, 2004; Li et al, 2005; Beuf et al, 2006;
Wilmes et al, 2007). Such pre-clinical applications require the use
of appropriately adapted or dedicated RF coils for small fields of
view, especially when the acquisition of functional MRI data is
considered. For dedicated clinical MRI research centres, the use
of such a coil arrangement for performing pre-clinical studies is
however more cost-effective compared to low-field benchtop
MRI systems that are becoming increasingly available for routine
pre-clinical investigations. The necessity to generate linear
magnetic field gradients over greater volume on clinical systems
limits the geometrical design and hence gradient system
performance in comparison to dedicated pre-clinical systems.
As a consequence, maximum gradient strengths and slew rates
are typically lower, which is also often desirable in order to
reduce patient peripheral nerve stimulation. It can however limit
EPI-based acquisitions such as DWI, rapid or ultra-high
resolution imaging.
In this study, the utility and sensitivity of anatomical and
functional MRI data, acquired using a high resolution RF coil on a
clinical 3T scanner, from two transgenic mouse models of
neuroblastoma was evaluated. In addition, the data were cross-
referenced to multiparametric data acquired from the same
transgenic mice on a dedicated pre-clinical 7T system, with a
particular focus on quantification of native longitudinal relaxation
time T1, and transverse relaxation rate R2*, previously shown to be
sensitive imaging biomarkers of treatment response and geno/
phenotype respectively (Jamin et al, 2013, 2014).
Use of the high resolution 3-channel/3-animal RF coil on a
clinical 3T platform yielded high quality T2-weighted anatomical
images of up to three mice simultaneously, with sufficient
resolution to accurately define and quantify the volume of
neuroblastomas arising within the abdomen of the transgenic
mice in vivo. The limited region of homogeneous field on dedicated
high field pre-clinical systems usually limits the acquisition of
functional imaging data from just a few representative slices across
the centre of a tumour. This is not the case for clinical systems
which allow functional measurements to be made across the whole
tumour. In addition, the multiple coil arrangement enabling
simultaneous scanning of several subjects enables high throughput
ideally suited for efficient cohort screening.
In addition, acquisition of whole mouse body data enables the
detection of any distant metastasis in the same imaging session,
a clear advantage when compared to the imaging performed on
high-field pre-clinical scanners with a more limited region of
magnetic field homogeneity. In cancer research, the increasing
development and use of more sophisticated orthotopic and
transgenic mouse models of primary and secondary disease
demands accurate non-invasive imaging methods to confirm
successful engraftment/propagation and longitudinal monitor-
ing of deep-seated tumours in vivo (Bielen et al, 2012; Jamin
et al, 2013; Graham et al, 2014). The coil arrangement used
herein can clearly be used to facilitate such tumour model
development, provides a potential screening tool to confirm
tumourigenesis, and may alleviate demand at research establish-
ments where the availability/capacity for high-field imaging is
limited.
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Figure 4. Simultaneous DCE-MRI at 3T. Parametric Ktrans maps obtained from three tumour-bearing transgenic mice from which DCE-MRI data
were simultaneously acquired using the high resolution 3-channel/3-animal MR RF coil on the 3T clinical scanner, showing a heterogeneous
distribution of vascular permeability/perfusion across all three neuroblastomas. Gadolinium uptake curves obtained from one mouse for ROIs
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The ability to quantify functional MRI data using the 3-channel/
3-animal RF coil at 3T was also explored. The primary objective
was quantification of tumour native T1 and R2*, imaging
biomarkers previously shown to be sensitive to successful
treatment response and haemodynamic vasculature within the
Th-MYCN and Th-ALKF1174L/Th-MYCN mice, measured at 7T
(Jamin et al, 2013, 2014). A key aim was to achieve a good
compromise between sufficient resolution, SNR and scan time for
quantitation of native T1 and R2*, rather than replicating sequences
and parameters routinely used on the 7T system. The excellent
linearity and positive correlation determined using the T1
phantom, and the strong significant correlation of tumour R2*
values in vivo, determined across both scanners, suggests that the
coil has sufficient sensitivity to acquire and accurately measure
native T1 and R2* in these transgenic mouse models of
neuroblastoma. As expected, the native T1 relaxation times in
tumours arising within the Th-MYCN mice were lower at 3T than
those previously reported at 7T (Sasaki et al, 2005; Jamin et al,
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Figure 5. Assessment of tumour response to CPM or CBZ treatment using the 3T platform. (A) T2-weighted coronal images acquired at 3T using
the high resolution 3-channel/3-animal MR RF coil from Th-MYCN transgenic mice bearing abdominal neuroblastomas prior to and 24h after
treatment with either saline (control) or CPM. Each tumour is delineated in yellow. Treatment with CPM resulted in a consistent and significant
(**Po0.01) reduction in tumour volume. Parametric maps of tumour (B) native T1 and (C) R2* acquired at 3T from Th-MYCN mice prior to and 24h
after treatment with either saline (control) or CPM. While treatment with CPM elicited a significant reduction in native T1 (**Po0.01), there was no
change in tumour R2*. Relative changes in tumour volume, native T1 and R2* determined from Th-MYCN mice treated with vehicle, or either CPM
or CBZ, are shown in (D) and (E) respectively. Data shown are the individual tumour median values and the mean±1 s.e.m. (***Po0.001,
**Po0.01).
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2013). The R2* values acquired in Th-MYCN and Th-ALK
F1174L/
Th-MYCN were B43% lower than those determined at 7T in this
study, are consistent with previously published values (Jamin et al,
2014), and with those reported from human tumours at 3T (Hallac
et al, 2012; Li et al, 2015; Bane et al, 2016; Panek et al, 2016). A
ratio of 2.14 was found between tumour R2* measured at 3 and 7T
(Figure 3B), which is in agreement with the expected linear
increase of the deoxyhaemoglobin R2* relaxivity with magnetic
field strength. An R2* ratio of 2.98 has been previously reported for
pure blood at 3 and 7T (Blockley et al, 2008). Neuroblastoma is
inherently hypervascular, hence quantitation of R2*, sensitive to
paramagnetic deoxyhaemoglobin, using intrinsic susceptibility
MRI is being actively investigated both pre-clinically and clinically
as a case-specific imaging biomarker for this paediatric cancer.
Encouragingly, the significantly slower R2* values determined at 3T
in the tumours arising within the Th-ALKF1174L/Th-MYCN mice is
wholly consistent with their impaired haemodynamic vascular
phenotype relative to that in the Th-MYCN mice, previously
established using intrinsic susceptibility MRI at 7T (Jamin et al,
2014), supporting the concept of ‘MRI genotyping’ in vivo
(Nieman et al, 2007).
Previous studies have described the acquisition of contrast-
enhanced MRI data from tumour-bearing rodents (individually or
in pairs) on clinical scanners, used to inform on either treatment
stratification or treatment response (Li et al, 2005;
Muruganandham et al, 2006; Wilmes et al, 2007; Egeland et al,
2009; Hompland et al, 2012). In our study we demonstrated the
feasibility of performing DCE-MRI simultaneously on three mice
using the 3-channel/3-animal RF coil at 3T, enabling the successful
pharmacokinetic analysis of Gd-contrast uptake curves in tumours
and surrounding organs. The use of volume coils with geometries
suitable for small rodents enabled high SNR DCE-MRI
measurements with sufficient resolution and coverage necessary
for pre-clinical tumour imaging. Furthermore, images are fully
compatible with processing tools developed for clinical diagnosis
and therapy planning software. This enables evaluation of methods
used for multi-parametric and sub-regional tumour analysis, signal
modelling (i.e. DCE and DWI models), or methodological MR
imaging development. In our study, clinically developed
software (MRIW, ADEPT) was used to calculate parametric T1
and R2* maps, and to perform pharmacokinetic modelling of the
DCE-MRI data.
Finally, the utility of the 3-channel/3-animal RF coil for
performing pre-clinical interventional trials at 3T was investigated
by assessing the anatomical and functional MRI response of
tumours arising in Th-MYCN transgenic mice to CPM, the current
standard treatment of care for children with high-risk neuroblas-
toma, or CBZ, currently in clinical trials for the treatment of
neuroblastoma. Treatment with CPM resulted in a significant
decrease in both tumour volume and native T1, consistent with
previous results acquired at 7T (Jamin et al, 2013). Significant
reductions in tumour native T1 following successful treatment with
a range of therapeutic regimes have been reported both pre-
clinically and clinically, hypothesised to be a consequence of the
release of proteins and paramagnetic ions into the extracellular
space (O’Connor et al, 2009; McSheehy et al, 2010; Jamin et al,
2013). Treatment with CBZ elicited a cytolentic response only.
Collectively these data demonstrate the ability to reveal differential
tumour response to treatment using this coil arrangement and
multiparametric MRI.
There are several methodological and logistical limitations to
performing pre-clinical investigations on clinical MRI systems. A
reliable and repeatable shim over a small volume of interest poses a
challenge, especially if EPI-based techniques (i.e. diffusion
weighted imaging) and spectroscopy are considered. This can
contribute to a decrease of R2* linearity measured at both fields.
However, differences in the positioning of the imaged volumes, and
the relatively high tumour heterogeneity apparent in Th-MYCN
tumours, should also be considered. There are practical considera-
tions in positioning lines for the remote, simultaneous adminis-
tration of contrast agents and delivery of gaseous anaesthetic from
the scanner control room, hence the use of injectable anaesthesia in
these studies. The utility of this coil arrangement for imaging
tumours arising in different anatomical sites within other
transgenic and orthotopic mouse models of cancer needs to be
established. Finally, significant effort must be made to conform to
institutional local rules and minimise any health risk associated
with cross-contamination, and to recognise the limited access to
clinical scanners during normal hospital operating hours.
In conclusion, we have demonstrated the utility and sensitivity
of a high resolution 3-channel/3-animal MR RF coil for performing
informative anatomical and functional MRI studies in transgenic
mouse models of neuroblastoma on a clinical 3T system. In this
way, simultaneous data acquisition in multiple tumour-bearing
animals can provide high efficiency/throughput for both pheno-
typic characterisation and trials of novel therapeutics, with
additional mechanistic insight provided by multiparametric MRI,
improving the accuracy of pre-clinical data and facilitating the
introduction of functional MRI biomarkers into aligned imaging-
embedded clinical trials.
ACKNOWLEDGEMENTS
The authors thank Dr Eva Kousi and Mr David Collins for
constructive discussions, the radiographers from the Royal
Marsden Hospital MRI unit, and staff from the Biological Services
Unit for their help. This study was supported by grants from
Cancer Research UK and EPSRC to the Cancer Imaging Centre at
ICR, in association with the MRC and Department of Health
(England) (C1060/A10334 and C1060/A16464), Cancer Research
UK (C46/A10588, C7224/A13407, C1060/A12752), NHS funding
to the NIHR Biomedicine Research Centre and the Clinical
Research Facility in Imaging, The Wellcome Trust (091763Z/10/Z),
and an EPSRC Platform Grant (EP/H046526/1).
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Bane O, Besa C, Wagner M, Oesingmann N, Zhu H, Fiel MI, Taouli B (2016)
Feasibility and reproducibility of BOLD and TOLD measurements in the
liver with oxygen and carbogen gas challenge in healthy volunteers and
patients with hepatocellular carcinoma. J Magn Reson Imaging 43(4):
866–876.
Benjaminsen IC, Graff BA, Brurberg KG, Rofstad EK (2004) Assessment of
tumor blood perfusion by high-resolution dynamic contrast-enhanced
MRI: a preclinical study of human melanoma xenografts. Magn Reson
Med 52(2): 269–276.
Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B,
Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H,
Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung N-K, Raynaud F,
Hallberg B, Robinson SP, Gray NS, Pearson ADJ, Eccles SA, Chesler L,
George Rani E (2012) The ALKF1174L mutation potentiates the oncogenic
activity of MYCN in neuroblastoma. Cancer Cell 22(1): 117–130.
Beuf O, Jaillon F, Saint-Jalmes H (2006) Small-animal MRI: signal-to-noise
ratio comparison at 7 and 1.5T with multiple-animal acquisition strategies.
Magn Reson Mater Phys, Biol Med 19(4): 202–208.
Bielen A, Box G, Perryman L, Bjerke L, Popov S, Jamin Y, Jury A, Valenti M,
Brandon AdH, Martins V, Romanet V, Jeay S, Raynaud FI, Hofmann F,
Robinson SP, Eccles SA, Jones C (2012) Dependence of Wilms tumor cells
BRITISH JOURNAL OF CANCER MRI of GEM tumour models on a clinical 3T scanner
8 www.bjcancer.com |DOI:10.1038/bjc.2017.251
on signaling through insulin-like growth factor 1 in an orthotopic
xenograft model targetable by specific receptor inhibition. Proc Natl Acad
Sci USA 109(20): E1267–E1276.
Bilgen M (2013) Feasibility and merits of performing preclinical imaging
on clinical radiology and nuclear medicine systems. Int J Mol Imaging
2013: 923823.
Blockley NP, Jiang L, Gardener AG, Ludman CN, Francis ST, Gowland PA
(2008) Field strength dependence of R1 and R 2* relaxivities of human
whole blood to prohance, vasovist, and deoxyhemoglobin. Magn Reson
Med 60(6): 1313–1320.
Brockmann MA, Kemmling A, Groden C (2007) Current issues and
perspectives in small rodent magnetic resonance imaging using clinical
MRI scanners. Methods 43(1): 79–87.
Chen F, De Keyzer F, Wang H, Vandecaveye V, Landuyt W, Bosmans H,
Hermans R, Marchal G, Ni Y (2007) Diffusion weighted imaging in small
rodents using clinical MRI scanners. Methods 43(1): 12–20.
Chesler L, Weiss WA (2011) Genetically-engineered murine models –
contribution to our understanding of the genetics, molecular pathology
and therapeutic targeting of neuroblastoma. Semin Cancer Biol 21(4):
245–255.
d’Arcy JA, Collins DJ, Padhani AR, Walker-Samuel S, Suckling J, Leach MO
(2006) Magnetic resonance imaging workbench: analysis and visualization
of dynamic contrast-enhanced MR imaging data. RadioGraphics 26(2):
621–632.
Dazai J, Bock NA, Nieman BJ, Davidson LM, Henkelman RM, Chen XJ (2004)
Multiple mouse biological loading and monitoring system for MRI. Magn
Reson Med 52(4): 709–715.
de Graaf RA, Brown PB, McIntyre S, Nixon TW, Behar KL, Rothman DL
(2006) High magnetic field water and metabolite proton T1 and T2
relaxation in rat brain in vivo. Magn Reson Med 56(2): 386–394.
de Jong M, Essers J, van Weerden WM (2014) Imaging preclinical tumour
models: improving translational power. Nat Rev Cancer 14(7): 481–493.
Doran SJ, d’Arcy J, Collins DJ, Andriantsimiavona R, Orton M, Koh D-M,
Leach MO (2012) Informatics in radiology: development of a research
PACS for analysis of functional imaging data in clinical research and
clinical trials. RadioGraphics 32(7): 2135–2150.
Egeland TAM, Simonsen TG, Gaustad J-V, Gulliksrud K, Ellingsen C,
Rofstad EK (2009) Dynamic contrast-enhanced magnetic resonance
imaging of tumors: preclinical validation of parametric images. Radiat Res
172(3): 339–347.
Fram EK, Herfkens RJ, Johnson GA, Glover GH, Karis JP, Shimakawa A,
Perkins TG, Pelc NJ (1987) Rapid calculation of T1 using variable flip
angle gradient refocused imaging. Magn Reson Imaging 5(3): 201–208.
Graham TJ, Box G, Tunariu N, Crespo M, Spinks TJ, Miranda S, Attard G,
de Bono J, Eccles SA, Davies FE, Robinson SP (2014) Preclinical evaluation
of imaging biomarkers for prostate cancer bone metastasis and response to
cabozantinib. J Natl Cancer Inst 106(4): dju033.
Hallac RR, Ding Y, Yuan Q, McColl RW, Lea J, Sims RD, Weatherall PT,
Mason RP (2012) Oxygenation in cervical cancer and normal uterine
cervix assessed using blood oxygenation level-dependent (BOLD) MRI
at 3T. NMR Biomed 25(12): 1321–1330.
Hompland T, Ellingsen C, Rofstad E (2012) Preclinical evaluation of
Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical
carcinoma interstitial fluid pressure. BMC Cancer 12(1): 544.
Inderbitzin D, Stoupis C, Sidler D, Gass M, Candinas D (2007) Abdominal
magnetic resonance imaging in small rodents using a clinical 1.5T MR
scanner. Methods 43(1): 46–53.
Jamin Y, Glass L, Hallsworth A, George R, Koh D-M, Pearson ADJ, Chesler L,
Robinson SP (2014) Intrinsic susceptibility MRI identifies tumors with
ALKF1174L mutation in genetically-engineered murine models of high-risk
neuroblastoma. PLoS ONE 9(3): e92886.
Jamin Y, Tucker ER, Poon E, Popov S, Vaughan L, Boult JKR, Webber H,
Hallsworth A, Baker LCJ, Jones C, Koh D-M, Pearson ADJ, Chesler L,
Robinson SP (2013) Evaluation of clinically translatable MR imaging
biomarkers of therapeutic response in the TH-MYCN transgenic mouse
model of neuroblastoma. Radiology 266(1): 130–140.
Jerome NP, Boult JKR, Orton MR, d’Arcy J, Collins DJ, Leach MO, Koh D-M,
Robinson SP (2016) Modulation of renal oxygenation and perfusion in rat
kidney monitored by quantitative diffusion and blood oxygen level
dependent magnetic resonance imaging on a clinical 1.5T platform. BMC
Nephrol 17(1): 142.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010)
Improving bioscience research reporting: the ARRIVE guidelines for
reporting animal research. PLoS Biol 8(6): e1000412.
Li K-L, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD,
McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM (2005)
Heterogeneity in the angiogenic response of a BT474 human breast cancer
to a novel vascular endothelial growth factor-receptor tyrosine kinase
inhibitor: Assessment by voxel analysis of dynamic contrast-enhanced
MRI. J Magn Reson Imaging 22(4): 511–519.
Li XS, Fan HX, Fang H, Song YL, Zhou CW (2015) Value of R2* obtained
from T2*-weighted imaging in predicting the prognosis of advanced
cervical squamous carcinoma treated with concurrent chemoradiotherapy.
J Magn Reson Imaging 42(3): 681–688.
Linn J, Schwarz F, Schichor C, Wiesmann M (2007) Cranial MRI of small
rodents using a clinical MR scanner. Methods 43(1): 2–11.
Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):
2202–2211.
McSheehy PMJ, Weidensteiner C, Cannet C, Ferretti S, Laurent D, Ruetz S,
Stumm M, Allegrini PR (2010) Quantified tumor T1 is a generic
early-response imaging biomarker for chemotherapy reflecting cell
viability. Clin Cancer Res 16(1): 212–225.
Muruganandham M, Lupu M, Dyke JP, Matei C, Linn M, Packman K,
Kolinsky K, Higgins B, Koutcher JA (2006) Preclinical evaluation of tumor
microvascular response to a novel antiangiogenic/antitumor agent
RO0281501 by dynamic contrast-enhanced MRI at 1.5T. Mol Cancer
Therapeut 5(8): 1950–1957.
Nieman BJ, Bishop J, Dazai J, Bock NA, Lerch JP, Feintuch A, Chen XJ,
Sled JG, Henkelman RM (2007) MR technology for biological studies in
mice. NMR Biomed 20(3): 291–303.
O’Connor JPB, Carano RAD, Clamp AR, Ross J, Ho CCK, Jackson A,
Parker GJM, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y,
Roberts C, Hope L, Cheung S, Reslan HB, Go MAT, Pacheco GJ, Wu X,
Cao TC, Ross S, Buonaccorsi GA, Davies K, Hasan J, Thornton P,
del Puerto O, Ferrara N, van Bruggen N, Jayson GC (2009) Quantifying
antivascular effects of monoclonal antibodies to vascular endothelial
growth factor: insights from imaging. Clin Cancer Res 15(21):
6674–6682.
Panek R, Welsh L, Dunlop A, Wong KH, Riddell AM, Koh D-M,
Schmidt MA, Doran S, McQuaid D, Hopkinson G, Richardson C,
Nutting CM, Bhide SA, Harrington KJ, Robinson SP, Newbold KL,
Leach MO (2016) Repeatability and sensitivity of T2* measurements in
patients with head and neck squamous cell carcinoma at 3T. J Magn Reson
Imaging 44(1): 72–80.
Rasmuson A, Segerstro¨m L, Nethander M, Finnman J, Elfman LHM,
Javanmardi N, Nilsson S, Johnsen JI, Martinsson T, Kogner P (2012)
Tumor development, growth characteristics and spectrum of genetic
aberrations in the TH-MYCN mouse model of neuroblastoma. PLOS One
7(12): e51297.
Sasaki M, Shibata E, Kanbara Y, Ehara S (2005) Enhancement effects and
relaxivities of gadolinium-DTPA at 1.5 versus 3 Tesla: a phantom study.
Magn Reson Med Sci 4(3): 145–149.
Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV,
Larsson HBW, Lee T-Y, Mayr NA, Parker GJM, Port RE, Taylor J,
Weisskoff RM (1999) Estimating kinetic parameters from dynamic
contrast-enhanced T1-weighted MRI of a diffusable tracer: Standardized
quantities and symbols. J Magn Reson Imaging 10(3): 223–232.
Ullman P, Junge S, Cowin G, Luescher K, Hennig J (2004) High field parallel
imaging in small rodents. In Proceedings of the ISMRM, p 1610.
Walker-Samuel S, Orton M, McPhail LD, Boult JKR, Box G, Eccles SA,
Robinson SP (2010) Bayesian estimation of changes in transverse
relaxation rates. Magn Reson Med 64(3): 914–921.
Wech T, Lygate CA, Neubauer S, Ko¨stler H, Schneider JE (2012) Highly
accelerated cardiac functional MRI in rodent hearts using compressed
sensing and parallel imaging at 9.4T. J Cardiovasc Magn Reson 14(1): P65.
Weiss WA, Aldape KD, Mohapatra G, Feuerstein BG, Bishop JM (1997)
Targeted expression of MYCN causes neuroblastoma in transgenic mice.
EMBO J 1611: 2985–2995.
Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li K-L,
Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW,
McShane TM, Lu Y, Brasch RC, Hylton NM (2007) AG-013736, a novel
inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth
and decreases vascular permeability as detected by dynamic contrast-
MRI of GEM tumour models on a clinical 3T scanner BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.251 9
enhanced magnetic resonance imaging. Magn Reson Imaging 25(3):
319–327.
Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ,
Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR,
Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA
(2010) Guidelines for the welfare and use of animals in cancer research.
Br J Cancer 102(11): 1555–1577.
Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F,
Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J,
Chou Y-C, Joly AH (2011) Cabozantinib (XL184), a novel MET and
VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis,
and tumor growth. Mol Cancer Therapeut 10(12): 2298–2308.
This work is licensed under the Creative Commons
Attribution 4.0 International License. To view a copy
of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) named above 2017
BRITISH JOURNAL OF CANCER MRI of GEM tumour models on a clinical 3T scanner
10 www.bjcancer.com |DOI:10.1038/bjc.2017.251
